Cell and gene therapy market to grow at 31.3% CAGR until 2030

Future treatments for DEB are expected to drive the sector’s growth.

The global dermatological cell and gene therapy (CGT) market is projected to grow at a compound annual growth rate of 31.3% through 2030, with sales expected to increase from $291min 2024 to $1.5b, according to GlobalData.

The sector’s expansion is attributed to therapeutic innovations, particularly from small to mid-sized pharmaceutical and biotech companies.

Future treatments for dystrophic epidermolysis bullosa (DEB) are expected to drive market growth, contributing $1.2b—or over 80%—of total CGT sales by 2030, said Momna Ali, Healthcare Analyst at GlobalData

In May 2023, the US Food and Drug Administration approved Vyjuvek (beremagene geperpavec) by Krystal Biotech, the first and only redosable gene therapy for DEB.

“There is an opportunity for geographical expansion for the existing players in the CGT space, Krystal Biotech’s Vyjuvek and Rheacell Pharmaceutical’s Amesanar, resulting in gene therapies potentially dominating the CGT market in dermatology disorders,” Ali added.